The scFv-FasLext lacks FcRII binding activity and bears a ligand for tumor target Ag that selectively enhances binding to the cancer targets with minimal non-specific cytotoxicity against Fas-expressing normal cells that lack scFv targeted Ag. This evidence concerns the gene FCGR2A and neoplasm.